Once you have established biologic efficacy and safety in early clinical material, your company’s real challenges are only beginning. Replicating the synthesis and bioanalysis of your biologic at different settings and among licensing or manufacturing partners introduces the risk of facility-based errors. And in order to commercialize your biologic, production volumes must be upscaled so intensely that new problems not encountered at smaller clinical volumes may severely hinder your timelines.
ExL Pharma’s “Technology Transfer for Biologics” conference recognizes that every instance of technology transfer will succeed or fail based on transparency of communications and the skill of the project manager. Exclusive case studies from industry leaders will help you guarantee biologic quality and accelerate to commercial stages after method transfer.
Managers, directors, senior directors, senior scientists, VPs, EVPs at biotech and biopharma companies responsible for: